Ivan Kairatov is a seasoned biopharma expert with an extensive background in the research and development of transformative genetic medicines. Having spent years navigating the complexities of viral vector technology and the rigorous demands of clinical trials, he offers a deep technical perspective on the evolving landscape of neuromuscular therapies. His expertise is particularly relevant today as the industry faces a critical juncture, balancing the promise of revolutionary gene therapies for Duchenne muscular dystrophy with the persistent challenges of safety and regulatory shifts.
In this conversation, we explore the nuances of microdystrophin expression across different age groups and the clinical benchmarks necessary to prove long-term efficacy. We also examine the protocols designed to manage adverse events like heart and liver inflammation, the strategic use of surrogate markers in the FDA approval process, and how next-generation therapy designs aim to surpass the limitations of earlier treatments.
Microdystrophin expression levels in older patients often drop significantly compared to younger cohorts. How do these specific protein production metrics influence the expected disease trajectory for boys over age eight, and what clinical benchmarks are most critical when measuring long-term motor function improvements?
The biological reality for boys over age eight is that they are often already on a visible path of physical decline, which makes the 42% microdystrophin expression level we observed in this cohort remarkably significant. While younger patients averaged higher at 71%, maintaining nearly half of normal protein production in older children provides a much-needed “shock absorber” for their muscle fibers. To translate these metrics into real-world benefits, we focus on a suite of motor function tests where nine of our volunteers showed statistically significant improvements after one year. By hitting that crucial 10% threshold of normal protein levels in 28 out of 30 participants, we are establishing a biological foundation that should, in theory, slow the progressive muscle wasting typical of Duchenne.
Clinical trials for gene therapies sometimes encounter cases of heart inflammation or asymptomatic liver injury. What specific protocols ensure these adverse events remain manageable during a study, and how do these safety profiles impact the long-term viability of treatments using viral delivery vectors?
Safety is our absolute priority, and the recent cases of heart inflammation and liver injury were managed through rigorous monitoring protocols that allowed both issues to resolve within weeks. We pay close attention to liver inflammation markers, and it is encouraging that the average levels in those receiving RGX-202 did not surpass the upper limit of normal. These events are often a reaction to the viral vector itself, which is why our alternate immune-suppressing drug regimen is so critical to the overall therapy design. If we can consistently show that these side effects are “easily managed” and do not lead to permanent damage, it strengthens the argument for the long-term viability of using viral packages to deliver life-saving genetic material.
Regulatory agencies are increasingly considering surrogate markers like microdystrophin expression to grant accelerated clearances. What are the practical steps for proving a correlation between protein levels and physical outcomes, and how does leadership turnover at oversight agencies affect the timing of high-stakes filings?
The practical step involves demonstrating that the presence of microdystrophin actually results in measurable physical changes, which we have done by linking expression levels to specific motor function gains. However, the regulatory environment is currently quite fluid; for instance, the resignation of Commissioner Marty Makary adds a layer of uncertainty to an agency already experiencing high turnover. We are strategically choosing to wait before filing our application to ensure we are aligning with a leadership team that hopefully carries a mandate for “rare disease flexibility.” While the market can be reactive—as seen by the 35% drop in share price following the safety update—our goal remains an accelerated approval by 2027 based on the strength of our surrogate data.
Utilizing larger protein versions and alternate immune-suppressing regimens represents a distinct shift in therapy design. What are the specific trade-offs when choosing between different microscopic viral packages, and how do these design choices specifically aim to provide better results than first-generation treatments?
The design of RGX-202 is a deliberate evolution from first-generation treatments; we chose a different microscopic virus to house a larger version of the microdystrophin protein. The trade-off often involves the complexity of the “package” size, but the goal is to produce a more robust form of the protein that can better protect the muscle fiber from necrosis. By combining this larger protein with a more sophisticated immune-suppression strategy, we are specifically aiming to avoid the pitfalls seen in earlier therapies, such as the potentially deadly liver complications that limited their use. This multi-pronged approach—better protein, different vector, and optimized immune management—is what we believe will finally offer a more durable and safer solution for patients.
What is your forecast for Duchenne gene therapy?
I believe we are entering an era of “refined precision” where the focus will shift from simply proving a therapy can work to optimizing how it is tolerated over a lifetime. While the industry has been rattled by recent safety hurdles and regulatory shifts, the data showing consistent microdystrophin expression across various age groups suggests that the underlying science is sound. My forecast is that by 2027, the FDA will establish more uniform standards for accelerated approval based on surrogate markers, which will finally allow these next-generation therapies to reach the broader population of boys who are currently running out of time. We will see a move away from “one-size-fits-all” viral delivery toward more tailored regimens that prioritize long-term hepatic and cardiac safety without sacrificing the high protein expression necessary to stop the disease in its tracks.
